Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 77

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 77
---
 is to become
due and payable on the second anniversary of the issuance of the note, provides for prepayment at any time without penalty, and accrues
simple interest at a rate equal 7% per annum. As of September 30, 2025, the Company has not borrowed any amounts under the Starwood Note.

On
May 19, 2025, Telomir Pharmaceuticals, Inc. the Company entered into an agreement to raise $3 million in equity financing through a direct
investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder. The transaction was structured as
a straight restricted common stock deal with no warrants. The Company issued 333,333 restricted shares of its common stock, no par value
(the “Common Stock”) at a purchase price of $3.00 per share, representing an 18% premium to the closing share price of the
Common Stock of $2.54 on the date of execution (the “Bayshore Financing”). The Company received the initial payment of $1
million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $2 million was received, for the issuance of 666,666
shares.

On
February 14, 2025, the Company filed a shelf registration statement with the SEC to facilitate the issuance of our common stock and entered
into an At The Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC under which the Company may
offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000. As of the date of filing of
this Form 10-Q, the Company has sold a total of 3,218,300 shares of its common stock, at a weighted average price of $2.12 for total
proceeds of $6,553,207, net of costs of $272,092

We
have incurred significant losses and negative cash flows from operations since inception and expect to incur additional losses until
such time that we can generate significant revenue and profit, which we do not expect to occur in the near future. We had negative cash
flow from operations of approximately $2.5 million for the nine months ended September 30, 2025. As of September 30, 2025, we had cash
and cash equivalents of approximately $7.3 million and an accumulated deficit of approximately $38.9 million